Harvard Bioscience Inc
NASDAQ:HBIO

Watchlist Manager
Harvard Bioscience Inc Logo
Harvard Bioscience Inc
NASDAQ:HBIO
Watchlist
Price: 0.505 USD 4.66% Market Closed
Market Cap: 22.3m USD

Wall Street
Price Targets

HBIO Price Targets Summary
Harvard Bioscience Inc

Wall Street analysts forecast HBIO stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for HBIO is 3.06 USD with a low forecast of 3.03 USD and a high forecast of 3.15 USD.

Lowest
Price Target
3.03 USD
500% Upside
Average
Price Target
3.06 USD
506% Upside
Highest
Price Target
3.15 USD
524% Upside
Harvard Bioscience Inc Competitors:
Price Targets
BANB
Bachem Holding AG
19% Upside
1548
Genscript Biotech Corp
40% Upside
NANOFH
Nanoform Finland Oyj
219% Upside
1521
Frontage Holdings Corp
29% Downside
WST
West Pharmaceutical Services Inc
35% Upside
RVU
Ryvu Therapeutics SA
115% Upside
688222
HitGen Inc
28% Downside
LAB
Standard BioTools Inc
53% Upside

Revenue
Forecast

Revenue Estimate
Harvard Bioscience Inc

For the last 8 years the compound annual growth rate for Harvard Bioscience Inc's revenue is -1%. The projected CAGR for the next 2 years is 2%.

-1%
Past Growth
2%
Estimated Growth
Estimates Accuracy
-3%
Average Miss

Operating Income
Forecast

Operating Income Estimate
Harvard Bioscience Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-81%
Average Miss

Net Income
Forecast

Net Income Estimate
Harvard Bioscience Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
N/A
Average
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is HBIO's stock price target?
Price Target
3.06 USD

According to Wall Street analysts, the average 1-year price target for HBIO is 3.06 USD with a low forecast of 3.03 USD and a high forecast of 3.15 USD.

What is Harvard Bioscience Inc's Revenue forecast?
Projected CAGR
2%

For the last 8 years the compound annual growth rate for Harvard Bioscience Inc's revenue is -1%. The projected CAGR for the next 2 years is 2%.

Back to Top